New Insights from the REDUCE-IT Study
Amarin Corporation plc (NASDAQ:AMRN) has made remarkable advancements in cardiovascular health research by unveiling new subgroup data from the significant REDUCE-IT cardiovascular outcomes trial, which focuses on VASCEPA/VAZKEPA (icosapent ethyl). These critical findings will be presented at the European Society of Cardiology (ESC) Congress, with the goal of enhancing scientific knowledge regarding cardiovascular risks.
Important Subgroup Findings
The subgroup analysis presented examines how baseline levels of small dense low-density lipoprotein cholesterol (sdLDL-C) affect the effectiveness of icosapent ethyl in reducing cardiovascular events. This essential research highlights the connection between sdLDL-C and cardiovascular health, helping clinicians customize treatment plans for patients at risk.
Understanding Eicosapentaenoic Acid (EPA)
Alongside the subgroup data, researchers will also share abstract findings that delve into the mechanistic role of eicosapentaenoic acid (EPA). Various studies will be discussed, including the relationship between triglyceride levels and cardiovascular incidents in patients experiencing acute coronary syndrome (ACS), as well as estimates of eligible patients for treatment in hospital settings.
Presentations Scheduled for ESC Congress 2024
Several key presentations are set to take place, including:
- Icosapent Ethyl by Baseline Small Dense Low-Density Lipoprotein Cholesterol - An analysis examining the effect of sdLDL-C on treatment outcomes, scheduled for August 30.
- Effect of Triglycerides on Cardiovascular Risk - A study exploring how triglyceride levels influence ACS outcomes on September 2.
- Candidate Prognosis for Eicosapentaenoic Acid Treatment Post-ACS - This discussion on September 2 will evaluate potential patient candidates following an ACS event.
- High Glucose Effects on Lipoprotein(a) Oxidation - An investigation into the biochemical interactions of EPA with Lp(a) oxidation, also scheduled for September 2.
Dedication to Cardiovascular Research
Amarin underscores its dedication to advancing cardiovascular care through ongoing research. The company is focused on addressing residual cardiovascular risks that remain after traditional lipid management strategies, with the aim of improving patient outcomes. Nabil Abadir, SVP and Chief Medical Officer, stated that the findings presented at the ESC will enhance clinical understanding of the effects of elevated triglycerides and the potential benefits of VASCEPA/VAZKEPA.
About Amarin Corporation
Amarin is a pioneering pharmaceutical company that is transforming the management of cardiovascular disease. With a global presence, it operates from various international locations and is committed to improving the understanding and treatment of cardiovascular risks.
Overview of the REDUCE-IT Study
The REDUCE-IT study is a landmark global trial designed to evaluate the efficacy of VASCEPA in reducing cardiovascular events among adults undergoing statin therapy. The study followed 8,179 patients across numerous clinical sites, focusing on adults with controlled LDL-C levels but elevated triglycerides, leading to significant findings in cardiovascular disease management.
Overview of VASCEPA
VASCEPA (icosapent ethyl) capsules represent a significant advancement in prescribed medications, specifically targeting individuals at high cardiovascular risk. As the first FDA-approved treatment consisting solely of icosapent ethyl, VASCEPA was launched in the United States to help reduce the risk of cardiovascular complications.
Indications and Safety Information
VASCEPA is indicated for use in conjunction with statin therapy to lower the risk of myocardial infarction and stroke in patients with elevated triglyceride levels. It is also prescribed to help reduce triglyceride levels in adults suffering from severe hypertriglyceridemia. It is essential for healthcare providers to consider the potential risks associated with VASCEPA, including an increased risk of atrial fibrillation and bleeding.
Contact Information
For more information regarding VASCEPA or Amarin, please reach out to the following media and investor contacts:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com
Frequently Asked Questions
What is the REDUCE-IT study?
The REDUCE-IT study is a crucial clinical trial that investigates how effective VASCEPA is in reducing cardiovascular events among patients with high triglyceride levels.
Where will the results be presented?
The results will be showcased at the European Society of Cardiology (ESC) Congress, contributing to a deeper understanding of cardiovascular issues.
What is VASCEPA?
VASCEPA (icosapent ethyl) is a prescription medication approved by the FDA that aims to lower the risk of cardiovascular events in patients with elevated triglyceride levels.
Who can benefit from VASCEPA?
Patients with cardiovascular conditions or those at risk due to elevated triglycerides may find VASCEPA beneficial as part of their treatment plan.
What are the common side effects of VASCEPA?
Common side effects reported include musculoskeletal pain, peripheral edema, constipation, and an increased risk of atrial fibrillation or bleeding.
